Preliminary studies have also shown the abnormal expression of the immune checkpoint molecule CEACAM1 in T-cells of patients with glioma, which was closely associated with clinical factors, including the pathological grading of tumours, patient functional status, and the level of cytokines [6]. Here, CEACAM1 is linked to central nervous system cancer.